title: Endothelin therapeutics in cancer: Where are we?
abstract: In human cancers, the autocrine and paracrine loop mediated by the aberrantly activation of endothelin-1 (ET-1) receptor (ET-1R) elicits pleiotropic effects, preferentially mediated by the scaffold protein β-arrestin 1 (β-arr1), on tumor cells and on the host microenvironment, providing a strong rationale for targeting ET-1 receptors. This review describes the most up-to-date preclinical and clinical results obtained by using ET-1 therapeutics. The previous negative clinical results of ET-1 therapeutics should not prevent us from setting the standard of this class of drugs for future well-designed clinical trials. The preclinical data obtained with the dual ETAR and ETBR antagonist macitentan indicate that this molecule, which targets cancer cells and tumor-associated microenvironmental elements, could be a cancer therapeutic option. The field of ET-1 therapeutics will be improved in the next decade, facilitated by the new knowledge on the genomic landscape of the human stroma and tumor, and by the low invasive approaches based on liquid biopsies for the discovery of predictive biomarkers. The information obtained from preclinical studies in patient-derived models and from the Cancer Genome Atlas will set the scene of precision medicine for cancer. Results from these studies are expected to open the possibility that ET-1R antagonists might be more efficacious as molecular cancer therapeutics, able to hamper the functional β-arr1-dependent signaling complexes, either alone or coupled with new targeted approaches.
authors.affiliation: Translational Research Functional Departmental Area, Regina Elena National Cancer Institute, Rome, Italy.
authors.forename: Laura
authors.initials: L
authors.lastname: Rosanò
authors.affiliation: Translational Research Functional Departmental Area, Regina Elena National Cancer Institute, Rome, Italy bagnato@ifo.it.
authors.forename: Anna
authors.initials: A
authors.lastname: Bagnato
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D019332:Endothelin-1 / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D044022:Receptor, Endothelin A / Q000187:drug effects*; D044023:Receptor, Endothelin B / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D019332:Endothelin-1; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B
keywords: cancer; endothelin-1; endothelin-1 receptor; target therapy; β-arrestin
references.citation: Cancer Biol Ther. 2013 Feb;14(2):184-92
references.pmid: 23192269
references.citation: Can J Physiol Pharmacol. 2015 Nov;93(11):935-44
references.pmid: 26440527
references.citation: Carcinogenesis. 2014 Apr;35(4):840-8
references.pmid: 24473118
references.citation: Cancer Res. 2005 Dec 15;65(24):11649-57
references.pmid: 16357176
references.citation: Br J Cancer. 2014 Feb 18;110(4):1027-33
references.pmid: 24357795
references.citation: J Mol Med (Berl). 2013 Mar;91(3):395-405
references.pmid: 22965194
references.citation: Nat Rev Cancer. 2013 Sep;13(9):637-51
references.pmid: 23884378
references.citation: Oncotarget. 2016 Jan 26;7(4):4009-23
references.pmid: 26675258
references.citation: Cancer Res. 2012 Oct 1;72(19):4909-19
references.pmid: 22865454
references.citation: Oncogene. 2013 Oct 17;32(42):5066-77
references.pmid: 23208497
references.citation: Oncogene. 2014 Mar 27;33(13):1725-35
references.pmid: 23584483
references.citation: Nat Med. 2008 Jan;14(1):28-36
references.pmid: 18157142
references.citation: Sci Signal. 2013 Apr 2;6(269):pl1
references.pmid: 23550210
references.citation: Cancer Res. 2015 Mar 15;75(6):1009-20
references.pmid: 25600647
references.citation: Blood. 2004 Oct 1;104(7):2107-15
references.pmid: 15213100
references.citation: Nature. 2011 Jun 30;474(7353):609-15
references.pmid: 21720365
references.citation: Neuro Oncol. 2014 Dec;16(12):1585-98
references.pmid: 25008093
references.citation: Prostate. 2007 May 15;67(7):701-13
references.pmid: 17342753
references.citation: PLoS One. 2014;9(6):e98818
references.pmid: 24901342
references.citation: Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2806-11
references.pmid: 19202075
references.citation: Cancer Res. 2014 Dec 15;74(24):7453-64
references.pmid: 25377471
references.citation: J Clin Invest. 2011 Jan;121(1):132-47
references.pmid: 21183790
references.citation: Nature. 1988 Mar 31;332(6163):411-5
references.pmid: 2451132
references.citation: Oncogene. 2013 Sep 12;32(37):4343-54
references.pmid: 23085755
references.citation: Clin Cancer Res. 2015 Oct 15;21(20):4630-41
references.pmid: 26106074
references.citation: Life Sci. 2014 Nov 24;118(2):179-84
references.pmid: 24530737
references.citation: J Neurooncol. 2016 Mar;127(1):23-32
references.pmid: 26645886
references.citation: Cancer Discov. 2012 May;2(5):401-4
references.pmid: 22588877
references.citation: Transl Oncol. 2012 Feb;5(1):39-47
references.pmid: 22348175
references.citation: Life Sci. 2012 Oct 15;91(13-14):544-9
references.pmid: 22480514
references.citation: Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1492-7
references.pmid: 16432186
references.citation: Cell Signal. 2014 Dec;26(12):2885-95
references.pmid: 25194819
references.citation: Oncogene. 2016 Jun 30;35(26):3432-42
references.pmid: 26522724
references.citation: J Biol Chem. 2014 Apr 4;289(14):10029-44
references.pmid: 24550382
references.citation: Int J Cancer. 2012 Mar 15;130(6):1264-72
references.pmid: 21445967